Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
Metrics: PDF 837 views | HTML 1051 views | ?
Tian Zhang1,*, Jing Wang1,*, Yanjun Su2, Xi Chen1, Qingna Yan3, Qi Li3, Leina Sun3, Yuwen Wang1, Puchun Er1, Qingsong Pang1 and Ping Wang1
1Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
*These authors have contributed equally to this work
Ping Wang, email: email@example.com
Qingsong Pang, email: firstname.lastname@example.org
Keywords: lung adenocarcinoma, classic EGFR mutations, micropapillary pattern, tyrosine kinase inhibitors
Received: October 29, 2016 Accepted: February 22, 2017 Published: March 23, 2017
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome 7. This study aimed to investigate the clinicopathologic characteristics of classic EGFR exon mutation in Chinese patients with TMN stage III lung adenocarcinoma who received radical surgery. A total of 1,801 lung adenocarcinomas were analyzed for mutations in EGFR; 35% exhibited mutation of classic EGFR exons. Clinical and pathologic characteristics of patients with EGFR exon 19 mutation were compared with those who harbored EGFR exon 21 mutation. Patients with EGFR exon 19 mutation had a higher overall survival (OS, p=0.023) than those harboring EGFR exon 21 mutation. Our results demonstrated that patients with a micropapillary pattern (MPP) pathologic type in EGFR exon 19 mutation had a higher OS (p=0.022), and patients with exon 19 mutation were more sensitive to EGFR–tyrosine kinase inhibitors (p=0.032). The results of the current study can be used in decision-making regarding the treatment of patients with classic EGFR exon mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.